Cubist Pharmaceuticals Inc. has met its safety objectives in a Phase 2 study of its treatment intended for prosthetic joint infections, the company announced today.
Cubicin (daptomycin for injection), Cubist’s therapy, treats skin and bloodstream infections related to Gram-positive bacteria, and the study employed it as a treatment in replacing infected prosthetic hip or knee joints following surgery.
Cubist (Nasdaq: CBST) officials noted the company’s objectives for the study – compare safety and tolerability of CUBICIN with current standards of treatment, including penicillin, teicoplanin or vancomycin. Results showed a similar number of adverse advents among the standard treatments.
In April, Cubist announced that it will no longer develop its drug ecallantide, a potential therapy to control bleeding in high-risk cardiac surgery patients.